Oncora Medical, a precision radiation oncology software company, and MD Anderson Cancer Center announced a strategic alliance focusing on building the next generation of precision medicine software for radiation oncology. During phase I, MD Anderson oncologists and information technology professionals will work with Oncora’s team of data scientists and engineers to install Oncora’s Precision Radiation […]
Novartis said the European Commission has approved Tafinlar(dabrafenib) in combination with Mekinist (trametinib) for the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer.
Janssen Research & Development, LLC said FDA has accepted for review a supplemental New Drug Application for ibrutinib (Imbruvica) for the treatment of patients with chronic graft-versus-host-disease after failure of one or more lines of systemic therapy.
Amgen announced the submission of a supplemental Biologics License Application to FDA and the European Medicines Agency for XGEVA (denosumab).
RedHill Biopharma Ltd., a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and cancer, said FDA has granted Yeliva (ABC294640) Orphan Drug designation for the treatment of cholangiocarcinoma.
ESSA Pharma Inc., a pharmaceutical company focused on the development of novel small molecule drugs for the treatment of prostate cancer, announced today the receipt of a $1.2 million payment from the Cancer Prevention Research Institute of Texas.
FDA granted regular approval to Tagrisso (osimertinib) for the treatment of patients with metastatic epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer, as detected by an FDA-approved test, whose disease has progressed on or after EGFR tyrosine kinase inhibitor therapy.
FDA approved Zejula (niraparib), a poly ADP-ribose polymerase inhibitor, for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.
Gamida Cell announced that orphan drug designation has been granted by the European Medicines Agency's Committee for Orphan Medicinal Products regarding NiCord as a treatment for haematopoietic stem cell transplantation, also commonly known as bone marrow transplantation.
Cota Healthcare announced the signing of a multi-year collaboration with Novartis Pharmaceuticals Corp. to help improve clinical and cost outcomes for breast cancer patients.
